

Chlorpheniramine References:

1. Doyle WJ, McBride TP, Skoner DP, Maddern BR, Gwaltney JM Jr, Uhrin M. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. *Pediatr Infect Dis J*. 1988 Mar;7(3):229-38. doi: 10.1097/00006454-198803000-00033. PMID: 3282216. VIRAL ILLNESS
2. Chang YL, Lin CS, Wang HW, Jian KR, Liu SC. Chlorpheniramine attenuates histamine-mediated aquaporin 5 downregulation in human nasal epithelial cells via suppression of NF- κ B activation. *Int J Med Sci*. 2017;14(12):1268-1275. doi:10.7150/ijms.21573
3. Chou KJ, Donovan MD. Distribution of antihistamines into the CSF following intranasal delivery. *Biopharm Drug Dispos*. 1997 May;18(4):335-46. doi: 10.1002/(sici)1099-081x(199705)18:4<335::aid-bdd22>3.0.co;2-w. PMID: 9158881.
4. Kayasuga R, Sugimoto Y, Watanabe T, Kamei C. Histamine H1 receptors are involved in mouse nasal allergic responses: a demonstration with H1 receptor-deficient mice. *Int Immunopharmacol*. 2002 May;2(6):745-50. doi: 10.1016/s1567-5769(02)00010-3. PMID: 12095164.
5. Van Toor BS, Buchwald A, Stengele E, Trenk D, Gercek C, de Mey CM. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. *Int J Clin Pharmacol Ther*. 2001 Apr;39(4):173-8. doi: 10.5414/cpp39173. PMID: 11332874.
6. Kirkegaard J, Secher C, Borum P, Mygind N. Inhibition of histamine-induced nasal symptoms by the H1 antihistamine chlorpheniramine maleate: demonstration of topical effect. *Br J Dis Chest*. 1983 Apr;77(2):113-22. doi: 10.1016/0007-0971(83)90017-7. PMID: 6347231.
7. SCHAFFER N, SEIDMON EE. The intranasal use of prophenpyridamine maleate and chlorprophenpyridamine maleate in allergic rhinitis. *Ann Allergy*. 1952 Mar-Apr;10(2):194-6. PMID: 14915367.
8. Suna Aydin, Suleyman Aydin, Could Antihistamines Help in the Treatment and Spread of COVID-19 Via Re-Modulating Cytokines and by Reducing Sneezing? *Acta Scientific Nutritional Health* 4.4 (2020) 172–173. https://actascientific.com/AS_NH/ASNH-04-0684.php.
9. H.W. Chang, et al., A common signaling pathway leading to degranulation in mast cells and its regulation by CCR1-ligand, *Allergy Eur. J. Allergy Clin. Immunol*. 75 (2020) 1371–1381, <https://doi.org/10.1111/all.14186>.
10. Sanchez-Gonzalez M, Rizvi SA, Torres J, Ferrer G. A Randomized Controlled Pilot Trial to Test the Efficacy of Intranasal Chlorpheniramine Maleate With Xylitol for the Treatment of Allergic Rhinitis. *Cureus*. Mar 31 2021;13(3):e14206. doi:10.7759/cureus.14206
11. Gwaltney JM Jr, Winther B, Patrie JT, Hendley JO. Combined antiviral-antimediator treatment for the common cold. *J Infect Dis*. 2002 Jul 15;186(2):147-54. doi: 10.1086/341455. Epub 2002 Jul 3. PMID: 12134249; PMCID: PMC7202474. VIRAL ILLNESS
12. Conti P, Caraffa A, Tetè G, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. *J Biol Regul Homeost Agents*. Sep-Oct 2020;34(5):1629-1632. doi:10.23812/20-2edit

13. Leah R.Reznikov^{a1}Michael H.Norris^{b1}RohitVashisht^cAndrew P.Bluhm^bDanmengLi^dYan-Shin J.Liao^aAshleyBrown^eAtul J.Butte^cDavid A.Ostrov^d. Identification of antiviral antihistamines for COVID-19 repurposing. <https://doi.org/10.1016/j.bbrc.2020.11.095> COVID
14. Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. *FASEB J.* 2020 May;34(5):6008-6016. doi: 10.1096/fj.202000502. Epub 2020 Apr 13. PMID: 32281695; PMCID: PMC7262065. COVID
15. Haiping Zhang¹ · Konda Mani Saravanan¹ · Yang Yang² · Md. Tofazzal Hossain^{1,6} · Junxin Li³ · Xiaohu Ren⁴ · Yi Pan⁵ · Yanjie Wei. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov COVID
16. <https://www.biospace.com/article/intranasal-approaches-have-potential-as-vaccines-and-therapies-for-covid-19/> COVID
17. <https://www.cebm.net/covid-19/mast-cell-stabilisers-leukotriene-antagonists-and-antihistamines-a-rapid-review-of-effectiveness-in-covid-19/> COVID RATIONALE
18. Graham AC, Temple RM, Obar JJ. Mast cells and influenza A virus: Association with allergic responses and beyond. *Front Immunol.* 2015;6:1–12.
19. Kilinc E, Baranoglu Y. Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection. *Anadolu Klin Tip Bilim Derg.* 2020;25(Supplement 1):111–8 COVID
20. He L, Ding Y, Zhang Q, Che X, He Y, Shen H, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. *J Pathol.* 2006 Nov;210(3):288–97. COVID
21. Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. *ecancer.* 2020;14:1022. COVID
22. Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX, et al. Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures. *Zhonghua Shao Shang Za Zhi.* 2020;36:6. COVID
23. Ramos L, Peña G, Cai B, Deitch EA, Ulloa L. Mast Cell Stabilization Improves Survival by Preventing Apoptosis in Sepsis. *J Immunol.* 2010;185(1):709–16. COVID
24. Hu Y, Jin Y, Han D, Zhang G, Cao S, Xie J, et al. Mast Cell-Induced Lung Injury in Mice Infected with H5N1 Influenza Virus. *J Virol.* 2012;86(6):3347–56. COVID
25. Lee J, Van Hecke O, Roberts N. Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19 [Internet]. The Centre for Evidence-Based Medicine, University of Oxford. 2020 [cited 2020 May 16]. Available from: <https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/> COVID
26. Gitahy Falcao Faria C, Weiner L, Petriguet J, Hingray C, Ruiz De Pellon Santamaria Á, Villoutreix BO, Beaune P, Leboyer M, Javelot H. Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19? *Med Hypotheses.* 2021 Jan 24;148:110508. doi: 10.1016/j.mehy.2021.110508. Epub ahead of print. PMID: 33571758; PMCID: PMC7830196. COVID
27. Reznikov LR, Norris MH, Vashisht R, Bluhm AP, Li D, Liao YJ, Brown A, Butte AJ, Ostrov DA. Identification of antiviral antihistamines for COVID-19 repurposing. *Biochem Biophys Res Commun.*

2020 Dec 3:S0006-291X(20)32140-9. doi: 10.1016/j.bbrc.2020.11.095. Epub ahead of print. PMID: 33309272; PMCID: PMC7713548. COVID

28. Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. *FASEB J.* 2020 May;34(5):6008-6016. doi: 10.1096/fj.202000502. Epub 2020 Apr 13. PMID: 32281695; PMCID: PMC7262065. COVID
29. Eldanasory OA, Eljaaly K, Memish ZA, Al-Tawfiq JA. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19. *Travel Med Infect Dis.* 2020 Sep-Oct;37:101874. doi: 10.1016/j.tmaid.2020.101874. Epub 2020 Sep 3. PMID: 32891724; PMCID: PMC7470786. COVID
30. Ennis M, Tiligada K. Histamine receptors and COVID-19. *Inflamm Res.* 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18. PMID: 33206207; PMCID: PMC7673069. COVID
31. Ge S, Wang X, Hou Y, Lv Y, Wang C, He H. Repositioning of histamine H₁ receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. *Eur J Pharmacol.* 2021 Jan 23;896:173897. doi:10.1016/j.ejphar.2021.173897. Epub ahead of print. PMID: 33497607; PMCID: PMC7826143. COVID

Chlorpheniramine & COVID Research plus our data:

1. Morán Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar Gómez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients. *Pulm Pharmacol Ther.* 2021 Jan 16;67:101989. doi: 10.1016/j.pupt.2021.101989. Epub ahead of print. PMID: 33465426; PMCID: PMC7833340. DexChlorpheniramine Clinical Trial.
2. Joselit Torres, Camille C. Go, Farah A. Chohan et al. Chlorpheniramine maleate nasal spray in COVID-19 patients: Case Series, 15 January 2021, PREPRINT (Version 1) available at Research Square [<https://doi.org/10.21203/rs.3.rs-138252/v1>]. Accepted for publication.
3. Westover JB, Ferrer G, Vazquez H, Bethencourt-Mirabal A, Go CC. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. *Cureus.* 2020 Sep 17;12(9):e10501. doi: 10.7759/cureus.10501. PMID: 32963923; PMCID: PMC7500730.
4. Go CC, Pandav K, Sanchez-Gonzalez MA, Ferrer G. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series. *Cureus.* 2020 Nov 3;12(11):e11315. doi: 10.7759/cureus.11315. PMID: 33173650; PMCID: PMC7645297.
5. A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-CoV-2 In Vitro. Gustavo Ferrer, Arian Betancourt, Camille Celeste Go, Hector Vazquez, Jonna B. Westover, Valeria Cagno, Caroline Tapparel, Marcos A. Sanchez-Gonzalez **doi:** <https://doi.org/10.1101/2020.11.23.394114>
6. In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2. Mark L Cannon, Jonna B. Westover, Reiner Bleher, Marcos A. Sanchez-Gonzalez, Gustavo A. Ferrer **doi:** <https://doi.org/10.1101/2020.12.02.408575>
7. Xylitol Blocks COVID. <https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf>
8. DNA Methylation Architecture of the ACE2 gene in Nasal Cells. <https://www.medrxiv.org/content/10.1101/2020.08.25.20182105v2.full.pdf>

9. Go CC, Pandav K, Sanchez-Gonzalez MA, Ferrer G. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series. *Cureus*. 2020;12(11):e11315. Published 2020 Nov 3. doi:10.7759/cureus.11315
10. Torres J, Go C, Camacho G, Sanchez-Gonzalez M, Ferrer G. Chlorpheniramine Maleate Nasal Spray In COVID-19 Patients: Case Series. *J Clin Exp Pharmacol*. 2021;10(2)(275):3. doi:10.35248/2161-1459.21.10.275
11. Xu W, Xia S, Pu J, Wang Q, Li P, Lu L, Jiang S. The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. *Front Microbiol*. 2018 Nov 6;9:2643. doi: 10.3389/fmicb.2018.02643. PMID: 30459739; PMCID: PMC6232386.
12. Sanchez-Gonzalez MA, Moskowitz D, Issuree PD, Yatzkan G, Rizvi SAA, Day K. A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation. *Infect Chemother*. Jun 12 2020;
13. Ferrer G, Sanchez-Gonzalez MA. Effective Nasal Disinfection as an Overlooked Strategy in Our Fight against COVID-19. *Ear Nose Throat J*. Mar 26 2021:1455613211002929. doi:10.1177/01455613211002929